| Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL … S Glatt, D Baeten, T Baker, M Griffiths, L Ionescu, ADG Lawson, A Maroof, ... Annals of the rheumatic diseases 77 (4), 523-532, 2018 | 239 | 2018 |
| Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial DJ Wallace, V Strand, JT Merrill, S Popa, AJ Spindler, A Eimon, M Petri, ... Annals of the rheumatic diseases 76 (3), 534-542, 2017 | 130 | 2017 |
| Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin DA Tatosian, Y Guo, AK Schaeffer, N Gaibu, S Popa, A Stoch, ... Diabetes Therapy 4, 431-442, 2013 | 62 | 2013 |
| A CCR2/5 inhibitor, PF-04634817, is inferior to monthly ranibizumab in the treatment of diabetic macular edema JD Gale, B Berger, S Gilbert, S Popa, MB Sultan, RA Schachar, D Girgenti, ... Investigative ophthalmology & visual science 59 (6), 2659-2669, 2018 | 22 | 2018 |
| mk-8742, a Hcv Ns5a Inhibitor with a Broad Spectrum of Hcv Genotypic Activity, Demonstrates Potent Antiviral Activity in Genotype-1 and-3 Hcv-infected Patients: 479 WW Yeh, C Lipardi, P Jumes, IM De Lepeleire, N Van Den Bulk, L Caro, ... Hepatology 58, 438A-439A, 2013 | 17 | 2013 |
| Studiul prevalentei markerilor serici ai infectiei cu virusurile hepatitelor in anamneza epidemiologica a populatiei G Molnar, S Popa, L Jebeleanu, C Damian Bacteriol Virusol Parazitol Epidemiol 39, 141-150, 1994 | 15 | 1994 |
| Magnetic resonance imaging of the hand and wrist in a randomized, double-blind, multicenter, placebo-controlled trial of infliximab for rheumatoid arthritis: Comparison of … C Beals, R Baumgartner, C Peterfy, A Balanescu, G Mirea, A Harabagiu, ... PLoS One 12 (12), e0187397, 2017 | 11 | 2017 |
| A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects W Krauwinkel, J Noukens, J Van Dijk, S Popa, T Ouatas, M De Vries, ... Journal of Clinical Pharmacy and Therapeutics 42 (3), 268-275, 2017 | 10 | 2017 |
| OP0108 bimekizumab, a monoclonal antibody that inhibits both IL-17A and IL-17F, produces a profound response in both skin and joints: Results of an early-phase, proof-of … S Glatt, F Strimenopoulou, P Vajjah, S Shaw, L Ionescu, S Popa, ... Annals of the Rheumatic Diseases 75 (Suppl 2), 95-96, 2016 | 10 | 2016 |
| Improvement of disease activity and reduction of severe flares following subcutaneous administration of an IL-6 monoclonal antibody (mAb) in subjects with active generalized … DJ Wallace, S Popa, AJ Spindler, A Eimon, T Gonzalez-Rivera, TO Utset, ... ARTHRITIS & RHEUMATOLOGY 66 (12), 3531-3531, 2014 | 10 | 2014 |
| SAT0492 Treatment Effects Measured by Dynamic Contrast Enhanced MRI and Ramris for Rheumatoid Arthritis C Beals, R Baumgartner, C Peterfy, A Balanescu, G Mirea, A Harabagiu, ... Annals of the rheumatic diseases 72 (Suppl 3), A748-A748, 2013 | 8 | 2013 |
| Antiviral activity, safety, and tolerability of multiple ascending doses of elbasvir or grazoprevir in participants infected with hepatitis C virus genotype-1 or-3 WW Yeh, IP Fraser, P Jumes, A Petry, I De Lepeleire, M Robberechts, ... Clinical Therapeutics 40 (5), 704-718. e6, 2018 | 6 | 2018 |
| VX-135, a once-daily nucleotide HCV polymerase inhibitor, was well tolerated and demonstrated potent antiviral activity when given with ribavirin in treatment-naïve patients … S Popa, A Berliba, N Ghicavii, AA Patat, RS Kauffman, J Krop, V Garg, ... Hepatology 58, 745A, 2013 | 6 | 2013 |
| A prevalence study of serum markers in hepatitis virus infection in the epidemiological anamnesis of the population GB Molnar, S Popa, L Jebeleanu, C Damian Bacteriologia, Virusologia, Parazitologia, Epidemiologia (Bucharest, Romania …, 1994 | 6 | 1994 |
| A Phase I/IIa Study Assessing 7-day Dosing of IDX21437 in Subjects Infected with Hepatitis C Virus (HCV): 1974 EJ Gane, E Sicard, S Popa, XJ Zhou, MF Temam, J Chen, D Frank, ... Hepatology 60, 1161A, 2014 | 5 | 2014 |
| 866 ALS-2200, A NOVEL ONCE-DAILY NUCLEOTIDE HCV POLYMERASE INHIBITOR, DEMONSTRATED POTENT ANTIVIRAL ACTIVITY IN TREATMENT-NAÏVE PATIENTS WITH COMPENSATED CIRRHOSIS OR GENOTYPE … P Marcellin, S Popa, A Streinu-Cercel, N Boyer, D Dospinoiu, A Patat, ... Journal of Hepatology, S355, 2013 | 5 | 2013 |
| ALS-2200, a novel once-daily nucleotide HCV polymerase inhibitor, demonstrates potent antiviral activity over 7 days in treatment-naïve genotype 1 (GT1) patients: 86 P Marcellin, S Popa, A Berliba, I Moscalu, N Boyer, RS Kauffman, ... Hepatology 56, 235A, 2012 | 4 | 2012 |
| Recovery of patients with gout L Rotaru, L Groppa, S Popa, T Nurseitova, C Cornea Revista de Ştiinţe ale Sănătăţii din Moldova 29 (3), 54-57, 2022 | 3 | 2022 |
| MK-3682, a HCV NS5B inhibitor with a broad spectrum of HCV genotypic activity, demonstrates potent antiviral activity in genotypes-1,-2, and-3 HCV-infected patients N Kim, W Gao, XS Glasgow, L Arrington, T Crumley, MF Temam, E Gane, ... 17th International Workshop on Clinical Pharmacology of HIV and Hepatitis …, 2016 | 3 | 2016 |
| In a 5-day monotherapy trial, MK-8408 demonstrates potent antiviral activity and improved resistance profile in HCV patients with genotypes 1, 2, and 3 infections E Asante-Appiah, W Marshall, E Gane, S Popa, P McMonagle, S Curry, ... Journal of Hepatology 2 (64), S402, 2016 | 3 | 2016 |
Liliana GroppaNicolae Testemitanu State University of Medicine & PharmacyVerified email at usmf.md
